Otsuka Pletal
Executive Summary
Safety concerns will be addressed in product labeling adequately, the company says in response to a Dec. 30 Public Citizen's Health Research Group letter to FDA ("The Pink Sheet" Jan. 4, In Brief). Cilostazol labeling will include tables offering guidance on concomitant use with several other cardiovascular-related drugs, the company says, and a physician education initiative will be part of the product launch. The firm says it is also in consultation with FDA to design a long-term safety study expected to last two years. Pletal has been "approvable" as a treatment for intermittent claudication since Sept. 18. The company says it is close to finalizing labeling, the last issue outstanding
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth